Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells

DOI: 10.1080/2162402X.2018.1472195

Keywords: immunotherapy, AML, CD33-CD16-CD123, dual targeting, single-chain triplebodies, NK cells, redirected lysis, therapeutic antibodies

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text